GU Cancers 2021 | ARROW: PSMA-targeted radioligand therapy plus enzalutamide in mCRPC

Frédéric Pouliot, MD, PhD, FRCSC, University Hospital of Quebec and Laval University, Quebec, Canada, shares an update on the Phase II ARROW (NCT03939689) trial at ASCO GU 2021. The ARROW trial is a randomized trial investigating the efficacy and safety of the prostate-specific membrane antigen (PSMA)-targeted I-131-1095 plus enzalutamide compared to enzalutamide alone, in patients with metastatic castration-resistant prostate cancer (mCRPC) who are chemotherapy naïve and have progressed on abiraterone. This interview took place during the 2021 Genitourinary Cancers Symposium.